Recent Updates
Recently added Catalysts
ACB Positive Sentiment Score: 80/100

Aurora Repurchases ~$47 Million Principal Amount of Convertible Notes, Saving $2.6 Million in Annualized Interest Payments; Balance Sheet Remains Among Strongest in Canadian Cannabis Industry NASDAQ | TSX

Key Takeaway: Aurora Cannabis announced the repurchase of approximately $46.6 million in convertible senior notes, saving the company $2.6 million in annualized interest payments. This transaction, completed at a 2.5% discount to par value, reflects the company's ongoing commitment to reducing debt and maintaining financial discipline. Following this repurchase, Aurora's outstanding notes will total around $103 million, bolstering its already strong balance sheet. The company aims to continue focusing on profitable growth in both global medical and Canadian adult use markets.

Market Sentiment Analysis

POSITIVE FACTORS

  • Repurchase of $47 million in convertible notes reduces annual interest payments by $2.6 million.
  • Strengthens Aurora's balance sheet, making it one of the strongest in the Canadian cannabis industry.
  • Focus on profitable growth in both global medical and Canadian adult use markets.

Full Press Release Details

Aurora Repurchases ~$47 Million Principal Amount
of Convertible Notes, Saving $2.6 Million in Annualized Interest Payments; Balance Sheet Remains Among Strongest in Canadian Cannabis
EDMONTON, AB, March 30, 2023 /CNW/ - Aurora Cannabis
Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today
announced that it has repurchased an aggregate of approximately $46.6 million (US$34.3 million) principal amount of its convertible senior
notes ("Notes") at a total cost, including accrued interest, of $45.6 million (US$33.6 million) in cash, saving $2.6 million
in annualized interest payments. Following completion of this repurchase, Aurora will have approximately $103 million (US$76 million)
of Notes outstanding.
The purpose of the transaction, which represents a
repurchase of a portion of the Notes at a 2.5% discount to par value, was to reduce the Company's debt and annual cash interest costs,
reinforcing our commitment to financial discipline. Aurora has repurchased an aggregate of approximately $366 million (US$269 million)
principal amount of its convertible senior notes since December 2021, resulting in annual cash interest savings of approximately $20 million
Aurora's balance sheet remains amongst the strongest
in the Canadian cannabis industry. Having achieved the goal of Adjusted EBITDA Profitability for the quarter ended December 31, 2022,
Aurora expects to continue to focus on profitable growth in both global medical and Canadian adult use markets.
This announcement does not constitute an offer to
sell, or a solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in
which such offering would be unlawful.
Aurora is opening the world to cannabis, serving both
the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people
improve their lives. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and
Greybeard, as well as CBD brands, Reliva and KG7. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana
Co. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven
by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders
in the medical, performance, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow
us on Twitter and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX
under the symbol "ACB".
Forward Looking Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan", "continue", "expect", "project",
"intend", "believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur.
Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's commitment
to financial discipline, including the repurchase of notes, future interest savings, and balance sheet strength, and the Company's
continued focus on profitable growth in both global medical and Canadian adult use markets.
These forward-looking statements are only predictions.
Forward looking information or statements contained in this news release have been developed based on assumptions management considers
to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation,
publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based
on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety
of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual
events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in
the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue
investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products,
customer experience and retention, the development of third party government and non-government consumer sales channels, management's
estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the
risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion
of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial
market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition,
and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including
the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading "Risk Factors" in the
Company's annual information form dated September 20, 2022 (the "AIF") and filed with Canadian securities regulators available
on the Company's issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC's website at www.sec.gov.
The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors
could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating
the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as expressly required by applicable securities law.
SOURCE Aurora Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2023/30/c7611.html
For further information: For Media: Michelle Lefler, VP, Communications
& PR, media@auroramj.com; For Investors: ICR, Inc., Investor Relations, aurora@icrinc.com
CO: Aurora Cannabis Inc.
CNW 17:30e 30-MAR-23

Frequently Asked Questions

What amount did Aurora Cannabis repurchase in notes?

Aurora repurchased approximately $46.6 million principal amount of convertible notes.

How much will Aurora save in annual interest payments?

Aurora will save $2.6 million in annualized interest payments.

What is Aurora's current outstanding notes balance?

Aurora will have around $103 million in outstanding notes after the repurchase.

How much has Aurora repurchased since December 2021?

Since December 2021, Aurora has repurchased about $366 million in notes.

What are Aurora's future market focuses?

Aurora aims to focus on profitable growth in global medical and Canadian adult use markets.

Last updated: Mar 30, 2023